Articles From: Zochem Investing in Its Customers’ Effortless Experience to Zogenix to Participate in Morgan Stanley Global Healthcare Conference 2014


Zochem, a subsidiary of Horsehead Holding Corp.
Sign-up for Zochem Investing in Its Customers’ Effortless Experience investment picks
2014/11/13
Zoe’s Kitchen, Inc. (“Zoës Kitchen” or the “Company”) today announced the pricing of its secondary public offering by certain of the Company’s stockholders (the “Selling Stockholders”) of 3,800,000 shares of the Company’s common stock at a price of $32.00 per share.
Sign-up for Zoe’s Kitchen, Inc. Announces Pricing of Secondary Public Offering of Common Stock investment picks
Zoe’s Kitchen, Inc. (“Zoës Kitchen” or the “Company”) (NYSE:ZOES) today announced that it has commenced a proposed secondary public offering of its common stock (the “Offering”). In the Offering, which is subject to market and other conditions, certain of the Company’s stockholders intend to offer 3,800,000 shares of common stock.
Sign-up for Zoe’s Kitchen, Inc. Commences Proposed Secondary Public Offering of Common Stock investment picks
Zoe's Kitchen, Inc. ("Zoës Kitchen" or the "Company") (NYSE:ZOES) announced the completion of the acquisition of three Zoës Kitchen restaurants, two restaurants under development, and area development rights in Louisiana from a franchisee for approximately $8.0 million in cash.
Sign-up for Zoës Kitchen Announces Acquisition of Franchised Restaurants in Louisiana investment picks
Zoe's Kitchen, Inc. ("Zoës Kitchen" or the "Company") (NYSE:ZOES) today reported financial results for the twelve and forty weeks ended October 6, 2014.
Sign-up for Zoës Kitchen Announces Third Quarter 2014 Results investment picks
Zoës Kitchen (“Zoe’s Kitchen, Inc.”) (NYSE:ZOES) today announced that it will host a conference call to discuss its third quarter 2014 financial results on Thursday, November 20, 2014 at 5:00 PM Eastern Time.
Sign-up for Zoës Kitchen to Announce Third Quarter 2014 Results on November 20, 2014 investment picks
Zoetis Inc. (NYSE: ZTS) today announced that its Board of Directors has adopted a one-year shareholder rights plan (the “Plan”) and declared a dividend distribution of one preferred share purchase right (a “Right”) for each outstanding share of the Company’s common stock.
Sign-up for Zoetis Adopts One-Year Shareholder Rights Plan investment picks
Zoetis Inc. (NYSE:ZTS) today announced the appointment of Roman Trawicki as President of its Global Manufacturing and Supply organization.
Sign-up for Zoetis Announces Appointment of Roman Trawicki as President of Global Manufacturing and Supply investment picks
Zoetis Inc. (NYSE: ZTS), the world’s leading animal health company, today announced that its Board of Directors has authorized a $500 million share repurchase program as part of its capital allocation plans.
Sign-up for Zoetis Announces Authorization of $500 Million Share Repurchase Program investment picks
Animal health company Zoetis Inc. (ZTS) said Tuesday it's board has approved a share buyback program of $500 million.
Sign-up for Zoetis board approves $500 mln share buyback program investment picks
The Board of Directors of Zoetis Inc. (NYSE:ZTS) declared a fourth quarter dividend payable to holders of the company’s common stock of $0.072 per share.
Sign-up for Zoetis Declares Fourth Quarter 2014 Dividend investment picks
Zoetis Inc. (NYSE:ZTS), the world’s leading animal health company, today hosted its first-ever Investor Day, discussing with investors and analysts the company’s leadership position in the animal health industry and the strategy and initiatives underway that will drive growth and create value for shareholders.
Sign-up for Zoetis Outlines Strategy and Initiatives Underway to Drive Growth and Create Shareholder Value at Investor Day Meeting investment picks
Zoetis Inc. (NYSE:ZTS) today announced that it has been named among the top 10 on Working Mother magazine’s "100 Best Companies for Working Mothers" list.
Sign-up for Zoetis Ranked Among Top Ten Companies for Working Mothers investment picks
Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2014.
Sign-up for Zoetis Reports Third Quarter 2014 Results investment picks
Shares of Zoetis (ZTS) extended losses in afternoon trade Tuesday, after the animal health company provided a downbeat profit and sales outlook for next year.
Sign-up for Zoetis shares fall further after downbeat 2015 outlook investment picks
Shares of Zoetis Inc. (ZTS) rallied Tuesday following a report that activist investor Bill Ackman has acquired a 10% stake in the animal-health products company.
Sign-up for Zoetis shares rally on report of Ackman stake investment picks
2014/11/17
By Chelsey Dulaney Zoetis Inc. has agreed to buy the animal health business of Abbott Laboratories for $255 million, less than a week after it surfaced that activist investor William Ackman has taken a roughly $2 billion stake in the company.
Sign-up for Zoetis to Buy Abbott's Animal Health Assets for $255 Million investment picks
Zoetis Inc. (NYSE: ZTS) will host a webcast and conference call at 8:30 a.m. (EST) on Tuesday, November 4, 2014.
Sign-up for Zoetis to Host Webcast and Conference Call on Third Quarter 2014 Financial Results investment picks
Zoetis Inc. (NYSE:ZTS) will participate in the Piper Jaffray 26th Annual Healthcare Conference on Tuesday, Dec.
Sign-up for Zoetis to Participate in Piper Jaffray 26th Annual Healthcare Conference investment picks
Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Animal & Dental Health Summit on Thursday, Dec.
Sign-up for Zoetis to Participate in the Bank of America Animal & Dental Health Summit investment picks
Zoetis Inc. (NYSE:ZTS) today announced an agreement to purchase animal health assets of Abbott for a purchase price of $255 million.
Sign-up for Zoetis to Purchase Assets of Abbott Animal Health investment picks
2014/11/18
By Michael Calia Zoetis Inc., the animal-health products maker at the center of the latest round of pharmaceutical deal talk, said Tuesday that its board has approved a $500 million share-buyback program.
Sign-up for Zoetis Unveils $500 Million Buyback Plan investment picks
By Michael CaliaPlan also comes a week after Zoetis adopted a poison pill plan Zoetis Inc., the animal-health products maker at the center of the latest round of pharmaceutical deal talk, said Tuesday that its board has approved a $500 million share-buyback program.
Sign-up for Zoetis unveils $500 million buyback plan investment picks
2014/11/18
By Michael Calia Zoetis Inc. said its board has approved a $500 million share-buyback program, stepping up its efforts to avoid a potential takeover battle driven by activist investors.
Sign-up for Zoetis Unveils $500 Million Stock Buyback Plan -- Update investment picks
Obtains global rights for treatment option in development for Dravet syndrome, a rare and catastrophic form of epilepsy that begins in infancy SAN DIEGO, Calif., Oct.
Sign-up for Zogenix Acquires U.K.-Based Brabant Pharma investment picks
2014/11/6
Conference Call and Webcast Today, November 6, at 4:30 p.m. ET Recent Business Highlights Submitted a supplemental New Drug Application (sNDA) for a modified formulation with potential abuse deterrent properties of Zohydro ® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, on September 30, with a target action date in late January 2015   Acquired Brabant Pharma, obtaining global rights for a Phase 3 product candidate with orphan drug designation in the U.S. and Europe for the treatment of Dravet syndrome    Exchanged waivers of regulatory exclusivity for extended-release hydrocodone products with Purdue Pharma, which includes $10 million in payments and potential sales royalties from Purdue    Signed a non-binding term sheet that is anticipated to provide a $20 million term loan plus an additional $4 million in a revolving line of credit Third Quarter 2014 Highlights Total prescriptions
Sign-up for Zogenix Reports Third Quarter 2014 Financial Results investment picks
SAN DIEGO, Sept.
Sign-up for Zogenix to Participate in Morgan Stanley Global Healthcare Conference 2014 investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Zochem Investing in Its Customers’ Effortless Experience to Zogenix to Participate in Morgan Stanley Global Healthcare Conference 2014
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent